Get the Stockscreener App
22.58
0.40%
-0.09
After Hours:
22.98
0.40
+1.77%
10 X Genomics Inc stock is traded at $22.58, with a volume of 887.66K.
It is down -0.40% in the last 24 hours and down -3.30% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
See More
Previous Close:
$22.67
Open:
$22.4
24h Volume:
887.66K
Relative Volume:
0.50
Market Cap:
$2.72B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-11.82
EPS:
-1.91
Net Cash Flow:
$-33.45M
1W Performance:
+1.67%
1M Performance:
-3.30%
6M Performance:
-39.83%
1Y Performance:
-45.26%
1-Day Range:
$22.18
$22.89
1-Week Range:
$21.07
$23.16
52-Week Range:
$15.28
$57.90
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
Susquehanna Fundamental Investments LLC Has $3.92 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Ensign Peak Advisors Inc Lowers Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) Short Interest Update - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by American Century Companies Inc. - MarketBeat
91,335 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Acquired by Hsbc Holdings PLC - MarketBeat
10x Genomics short call reiterated at Hedgeye, sees potential for 50% downside - Seeking Alpha
10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by State of New Jersey Common Pension Fund D - MarketBeat
Edgestream Partners L.P. Sells 24,335 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Magnetar Financial LLC Buys 105,500 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Seven Eight Capital LP Cuts Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
10x Genomics (NASDAQ:TXG) investors are sitting on a loss of 85% if they invested three years ago - Yahoo Finance
Granite Investment Partners LLC Sells 48,020 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Primecap Management Co. CA Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Inc (TXG) Stock Price Up 6.5% on Sep 19 - GuruFocus.com
Parse Nixes 10x Genomics Cell-Analysis Patent at Tribunal (1) - Bloomberg Law
TD Asset Management Inc Sells 95,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer - StockTitan
Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer - PR Newswire
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow - Simply Wall St
SVB Wealth LLC Decreases Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (NASDAQ:TXG) Trading Down 5.8% - MarketBeat
10x Genomics, Inc. Expected to Post Q3 2024 Earnings of ($0.27) Per Share (NASDAQ:TXG) - MarketBeat
10x Genomics (NASDAQ:TXG) Shares Up 3.5% - MarketBeat
10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research - StreetInsider.com
10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research - StockTitan
In-Depth Examination Of 11 Analyst Recommendations For 10x Genomics - Benzinga
10 Promising Biotech Stocks to Invest in (September 2024) - Securities.io
11,081 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) Receives $31.46 Average Target Price from Analysts - MarketBeat
Justin Mcanear, ex-CFO of 10x Genomics, sells shares worth over $66k - Investing.com
10x genomics executive sells over $98,000 in company stock - Investing.com
Baillie Gifford & Co. Trims Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - StockTitan
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - Financial Times
First Horizon Advisors Inc. Grows Position in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - Yahoo Finance
10x Genomics (MEX:TXG) Cash Ratio : 3.42 (As of Jun. 2024) - GuruFocus.com
Sumitomo Mitsui Trust Holdings Inc. Acquires 2,521,289 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Cwm LLC Sells 44,067 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x Genomics (STU:1KJ) EV-to-Revenue : 3.63 (As of Aug. 18, 2024) - GuruFocus.com
10x Genomics (MEX:TXG) Market Cap : MXN48,890 Mil (As of Aug. 18, 2024) - GuruFocus.com
10x Genomics (MEX:TXG) EV-to-FCF : -75.73 (As of Aug. 17, 2024) - GuruFocus.com
TXG (10x Genomics) Net Change in Cash : $49.0 Mil (TTM As of Jun. 2024) - GuruFocus.com
TXG (10x Genomics) Marketable Securities : $0.3 Mil (As of Jun. 2024) - GuruFocus.com
10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel - Longview News-Journal
TXG (10x Genomics) Cash-to-Debt : 4.25 (As of Jun. 2024) - GuruFocus.com
SG Americas Securities LLC Has $1.97 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Price-to-Free-Cash-Flow : N/A (As of Aug. 15, 2024) - GuruFocus.com
TXG (10x Genomics) EBITDA : $-187.7 Mil (TTM As of Jun. 2024) - GuruFocus.com
SG Americas Securities LLC Has $1.97 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):